Canada based Obesity Clinical Trials & Research Studies Near You (Updated 8/25)

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383

Recruiting

The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.

Gender:

ALL

Ages:

Between 12 years and 15 years

Trial Updated:

07/02/2025

Locations: Neighborhood Healthcare, Escondido, California +96 locations

Neighborhood Healthcare, Escondido, California

Clinical Neuroscience Solution, Orlando, Florida

TMH Physician Partners Endo, Tallahassee, Florida

Children's Healthcare Atlanta, Atlanta, Georgia

Columbus Research Foundation, Columbus, Georgia

Eastside Bariatric and Gen Surg, Snellville, Georgia

Solaris Clinical Research, Meridian, Idaho

Synexus Clinical Research US Inc.-Chicago, Chicago, Illinois

Indiana University Hospital, Indianapolis, Indiana

University Of Iowa Hospitals and Clinics, Iowa City, Iowa

Pennington Biom Res Ctr, Baton Rouge, Louisiana

Barry J. Reiner, MD LLC, Baltimore, Maryland

University of Minnesota, Minneapolis, Minnesota

Mississippi CTR for ADV MED, Madison, Mississippi

UBMD Peds-Div of Endo/Diabetes, Buffalo, New York

WakeMed Childn Endo-Dbt_Raleig, Raleigh, North Carolina

Valley Weight Loss Clinic, Fargo, North Dakota

Centricity Research - Ohio, Columbus, Ohio

PriMed Clinical Research, Dayton, Ohio

UPMC Child Hosp-Pittsburgh, Pittsburgh, Pennsylvania

Coastal Carolina Research Ctr, North Charleston, South Carolina

Clinical Neuroscience Solutions, Memphis, Tennessee

Texas Diabetes Institute, San Antonio, Texas

Clinical Trials of Texas Inc, San Antonio, Texas

Health Res of Hampton Roads, Newport News, Virginia

Virginia Commonwealth Univ, Richmond, Virginia

UZ Brussel - Universitair Ziekenhuis Brussel, Brussel, Not set

Cliniques universitaires Saint-Luc, Bruxelles, Not set

UZA - Universitair Ziekenhuis Antwerpen, Edegem, Not set

Uz Leuven, Leuven, Not set

Alberta Children's Hospital, Calgary, Alberta

Stollery Children's Hospital, Edmonton, Alberta

BC Children's Hospital, Vancouver, British Columbia

Markham Stouffville Hosp, Markham, Ontario

The Hospital for Sick Children, Toronto, Ontario

McMaster Children's Hospital, West Hamilton, Ontario

Maison de Sante Prevention, Montreal, Quebec

McGill Uni Health Ctre - Glen Site, Montreal, Quebec

Aalborg Universitetshospital, Aalborg, Not set

Aarhus Universitetshospital, Steno Diabetes Center Aarhus, Aarhus, Not set

Holbæk Sygehus, Holbæk, Not set

Centre Hospitalier Universitaire de Lille-Hopital Jeanne de Flandre, Lille Cedex, Not set

Fondation Lenval Nice, Nice, Not set

Ap-Hp-Hopital Armand Trousseau, Paris, Not set

Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle, Rouen cedex, Not set

Hopital Des Enfants-1, Toulouse Cedex 9, Not set

Kinderkrankenhaus Bochum, Bochum, Not set

Universitätsmedizin Göttingen - Klinik für Kinder-und Jugendmedizin, Göttingen, Not set

Auf der Bult - Klinik für Diabetologie, Endokrinologie, Gastroenterologie und Klinische Forschung, Hannover, Not set

Universitätsklinikum Leipzig - Klinik und Poliklinik für Kinder- und Jugendmedizin, Leipzig, Not set

Deutsches Zentrum für Kinder- und Jugendgesundheit (DZKJ), Ulm, Not set

Universitätsklinikum Ulm für Kinder- und Jugendmedizin, Ulm, Not set

U.G.H. "Attikon", Pediatric Endocrinology Outpatient Clinic, Athens, Not set

P & A Kyriakou Childrens' Hospital, Goudi/Athens, Not set

General University of Patra - Paediatric Department, Patra, Not set

'Ippokrateio' General Hospital of Thessaloniki, Thessaloniki, Not set

Ippokrateio Gen Hosp of Thessaloniki, 1st Pediatric Clinic, Thessaloniki, Not set

IRCCS Meyer Firenze, Florence, Toscana

Ospedale dei Bambini "Vittore Buzzi", Milan, Not set

Bambin Gesù, Roma, Not set

IRCCS materno infantile Burlo Garofolo, Trieste, Not set

AOU Integrata di Verona - Ospedale Civile Maggiore, Verona, Not set

CHRISTUS - Latam Hub Excellence and Innovation Center, Monterrey, Nuevo León

Centro de Estudios de Investigación Metabólicos y Cardio, Ciudad Madero, Tamaulipas

Consultorio de Endocrinología y Pediatría, Puebla, Not set

Klinika Pediatrii, Endokrynologii, Diabetologii I chorób Metabolicznych, Uniwersyteckiego Szpitala Klinicznego in Wrocław, Wrocław, Dolnośląskie

Copernicus Podmiot Leczniczy Sp. z o.o., Gdańsk, Not set

Górnośląskie Centrum Zdrowia Dziecka Im. Św. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 SUM w Katowicach, Katowice, Not set

Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie, Rzeszów, Not set

ELIPSA - Elżbieta Lipska praktyka lekarska Ośrodek Endokrynologii i Diabetologii Dziecięcej, Stanisławów Pierwszy Nieporęt, Not set

Instytut ''Pomnik - Centrum Zdrowia Dziecka'', Warszawa, Not set

Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko, Zabrze, Not set

UMED Clinical Trials sp. z o.o., Łódź, Not set

King Abdulaziz Hospital-Al Ahsa-National Guard, Al Ahsa, Not set

National Guard Hospital - Jeddah, Jeddah, Not set

King Khaled University Hospital,King Saud Univ. Med. City, Riyadh, Not set

King Faisal Specialist Hospital & Research Centre, Riyadh, Riyadh, Not set

National Guard Hospital_Riyadh, Riyadh, Not set

Barn- och ungdomsmedicinsk mottagning Falun lasarett, Falun, Not set

Hallands sjukhus Halmstad, Halmstad, Not set

Barnöverviktsenheten, SUS Malmö, Malmö, Not set

Sundsvalls sjukhus, Sundsvall, Not set

Akademiska sjukhuset Uppsala, Uppsala, Not set

Birmingham Children's Hospital, Birmingham, Not set

University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, Not set

Leeds Children's Hospital, Leeds, Not set

Alder Hey Children's Hospital, Liverpool, Not set

Paediatric Services - UCL, London, Not set

Sheffield Children's Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

Conditions: Obesity

Register for Updates

Learn More ›

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

NCT06780449

Recruiting

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/27/2025

Locations: Valley Clinical Trials, Covina, California +36 locations

Valley Clinical Trials, Covina, California

Diablo Clinical Research, Inc., Walnut Creek, California

Yale University School Of Medicine, New Haven, Connecticut

East West Medical Research Institute_Honolulu, Honolulu, Hawaii

L-MARC Research Center, Louisville, Kentucky

StudyMetrix Research LLC, Saint Peters, Missouri

Spartanburg Medical Research, Spartanburg, South Carolina

Holston Medical Group_Bristol, Bristol, Tennessee

North Texas Endocrine Center, Dallas, Texas

Washington Cntr Weight Mgmt, Arlington, Virginia

CHU Helora - Site Warquignies, Boussu, Not set

Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie, Bruxelles, Not set

UZA - UZ Antwerpen - Department of Endocrinology, Edegem, Not set

UZ Leuven - Endocrinology, Leuven, Not set

Dr. M.B. Jones Inc, Victoria, British Columbia

Nova Scotia Health Authority, Halifax, Nova Scotia

Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario

Alpha Recherche Clinique - Lebourgneuf, Quebec, Not set

Aarhus Universitetshospital, Steno Diabetes Center Aarhus, Aarhus, Not set

Sydvestjysk Sygehus Esbjerg, Esbjerg, Not set

Center for Klinisk Metabolisk Forskning, Hellerup, Not set

Hvidovre Hospital Endokrinologisk forsknings afsnit 159, Hvidovre, Not set

Sjællands Universitetshospital, Køge, Not set

Unidade Local De Saude De Matosinhos E.P.E., Senhora Da Hora, Matosinhos, Matosinhos

APDP - Associação Protectora dos Diabéticos de Portugal, Lisboa, Not set

CUF Descobertas, Lisboa, Not set

Hospital Cuf Descobertas S.A., Lisboa, Not set

Unidade Local de Saude de Sao Joao E.P.E, Porto, Not set

Hospital Luz Arrabida, S.A., Vila Nova de Gaia, Not set

Southmead Hospital, Bristol, Not set

Addenbrooke's Hospital_Cambridge, Cambridge, Not set

WISDEM Centre, Coventry, Not set

University Hospital Aintree, Liverpool, Not set

Blizard Institute_Royal London Hospital, London, Not set

Joint Clinical Research Facility - Swansea, Swansea, Not set

Musgrove Park Hospital, Taunton, Not set

Conditions: Obesity

Register for Updates

Learn More ›

Fibrosis Lessens After Metabolic Surgery

NCT06374875

Recruiting

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepa... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

04/17/2025

Locations: Banner Health Center, Phoenix, Arizona +21 locations

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity

Register for Updates

Learn More ›

BariaPSY: the Data Bank

NCT05602805

Recruiting

Multimorbidity, the co-occurrence of several chronic conditions, is a growing phenomenon that poses new challenges for clinicians and researchers. The association between a mental health disorder and a physical health disorder represents a particularly frequent subtype of multimorbidity and is associated with greater severity and higher consumption of care. It is essential and urgent to explore the specific pathophysiology of this subtype of multimorbidity in order to develop adapted therapeutic... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/07/2024

Locations: IUCPQ, Québec, Quebec

Conditions: Bariatric Surgery Candidate, Obesity

Register for Updates

Learn More ›

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

NCT06396416

Recruiting

OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/30/2024

Locations: London Health Sciences Centre, London, Ontario

Conditions: Obesity, Chronic Kidney Disease

Register for Updates

Learn More ›

Predicting Appendicular Lean and Fat Mass With Bioelectrical Impedance Analysis Among Adult Patients With Obesity.

NCT06545435

Recruiting

This study aims to develop and cross-validate novel bioelectrical impedance analysis (BIA) equations for predicting appendicular soft tissue masses, specifically fat mass (FM) and appendicular lean mass (ALM), in a sample of Caucasian adult subjects affected by obesity. The research will compare these new BIA equations with three established BIA-derived prediction models and validate them using dual-energy X-ray absorptiometry (DXA) and magnetic resonance imaging (MRI) data. This study utilizes... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/22/2024

Locations: Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana +8 locations

Conditions: Obesity

Register for Updates

Learn More ›

Impact of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults

NCT06265246

Recruiting

Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) suppl... Read More

Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption. Read Less

Gender:

ALL

Ages:

Between 19 years and 30 years

Trial Updated:

08/14/2024

Locations: University of Saskatchewan, Saskatoon, Saskatchewan

Conditions: Osteoporosis, Obesity

Register for Updates

Learn More ›

Single Anastomosis Versus Standard Duodenal Switch

NCT04767490

Recruiting

Bilio-Pancreatic diversion with Duodenal Switch (BPD-DS) is the most effective bariatric procedure in terms of long-term weight loss and remission rate of Type 2 Diabetes. However, its technical difficulty and increased risk of long-term nutritional deficiencies have been a major hindrance to its diffusion. Recently, a " simplified " technique of Duodenal-Switch has been proposed by Sanchez-Pernaute et al. This technique involves the creation of a Sleeve Gastrectomy, transection of the first du... Read More

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

08/06/2024

Locations: Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec

Conditions: Obesity, Morbid Obesity

Register for Updates

Learn More ›

Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery

NCT05242835

Recruiting

Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging an... Read More

Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question. Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies. With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap. Read Less

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

08/06/2024

Locations: Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec

Conditions: Obesity, Obesity, Morbid

Register for Updates

Learn More ›

Effect of Acute ObeEnd Exposure on Factors Regulating Appetite

NCT06487234

Recruiting

n Canada, over 60% of adults are classified as overweight and obese resulting in a public health crisis including increasing health care costs and negatively impacting the well-being of many Canadians. To overcome these barriers, the ObeEnd device, manufactured by WAT Medical Enterprise, is a new and innovative wellness technology that uses electrical pulses to stimulate acupressure point PC6 to help control appetite. PC6 stimulation could potentially modulate appetite and restore gastric dysfun... Read More

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

07/02/2024

Locations: Concordia University, Montreal, Quebec

Conditions: Obesity

Register for Updates

Learn More ›

RMR Monitoring Feasibility and Acceptability

NCT06467578

Recruiting

Obesity is a leading risk factor for chronic diseases such as type 2 diabetes, cancer, and cardiovascular disease. Generic weight management programs that target dietary intake and physical activity have been shown to be ineffective in maintaining weight loss beyond a 6-month period. Personalizing weight management programs produces more weight loss than generic programs, possibly through improved self-efficacy (confidence in one's ability to control weight through behavior). One way to personal... Read More

Obesity is a leading risk factor for chronic diseases such as type 2 diabetes, cancer, and cardiovascular disease. Generic weight management programs that target dietary intake and physical activity have been shown to be ineffective in maintaining weight loss beyond a 6-month period. Personalizing weight management programs produces more weight loss than generic programs, possibly through improved self-efficacy (confidence in one's ability to control weight through behavior). One way to personalize diet goals for individuals is by resting metabolic rate (RMR; 'metabolism'). This study will explore adherence and satisfaction of 6-weeks repeated at-home measures of metabolism using a portable device in healthy adults with and without obesity. Relationships among adherence and satisfaction outcomes to health behavior variables will be explored using dietary recalls, exercise monitors and questionnaires. Investigators will conduct a 6-week, one-arm feasibility study in order to address these questions. Twenty men and women ages 19-65 will be recruited (up to n=25 participants), among which 10 participants will have a body mass index (BMI) of ≥30kg/m2 (classified as having obesity), and the remaining 10 participants will have a body mass index (BMI) of \< 29.9kg/m2 (classified as not having obesity). The baseline study visit will evaluate participant's anthropometric measures, RMR using the ParvoMedics TrueOne 2400 and Breezing indirect calorimeters, psychological and behavioural related parameters. An activPAL device will be provided to measure participant physical activity. Completion of a 3-day diet record following the baseline study visit, in which participants keep a record of all food and beverages consumed over 2 weekdays and 1 weekend, is required. Participants will be asked to use the Breezing device from home to measure their RMR one time/week on the same day of the week (± one day) and at the same time each morning for six consecutive weeks following the baseline visit. A weekly Qualtrics survey will be sent to participants to monitor adherence. A follow-up visit after the six weeks will assess participant's body composition using a Dual X-ray Absorptiometry (DEXA), in addition to completion of a user satisfaction interview with a study team member for descriptive analysis. The measures taken at the baseline study visit will be repeated at the follow-up visit. Read Less

Gender:

ALL

Ages:

Between 19 years and 65 years

Trial Updated:

06/20/2024

Locations: University of British Columbia - Okanagan Campus, Kelowna, British Columbia

Conditions: Metabolism, Obesity, Weight Loss

Register for Updates

Learn More ›

Exogenous Ketones and Appetite

NCT06327464

Recruiting

People with obesity have different appetitive responses to stimuli compared to people without obesity. For example, people with obesity have a blunted postprandial ghrelin ('hunger' hormone) response, lower glucagon-like peptide 1 (GLP-1) and peptide-YY (PYY; associated with satiety) compared to people without obesity. Given the favorable effects of exogenous ketones on appetite previously observed in healthy adults of normal body weight, it is possible that these supplements can alter appetite... Read More

People with obesity have different appetitive responses to stimuli compared to people without obesity. For example, people with obesity have a blunted postprandial ghrelin ('hunger' hormone) response, lower glucagon-like peptide 1 (GLP-1) and peptide-YY (PYY; associated with satiety) compared to people without obesity. Given the favorable effects of exogenous ketones on appetite previously observed in healthy adults of normal body weight, it is possible that these supplements can alter appetite hormones in a manner that may closer match that observed in people without obesity. To explore this research question, investigators will conduct a randomized single-blind cross over study to characterize appetite and dietary intake after ingestion of an exogenous ketone supplement within adults with obesity (compared a control condition without exogenous ketones) and compared to adults without obesity. The research team will also explore differences in postprandial energy expenditure and fuel utilization. Twenty-two healthy young- and middle-aged adults will be included (up to n=26 enrolled). In addition to a baseline visit to measure body composition, participants will undergo two 4.5-hour study visits, one of which will include a ketone diol supplement and one will have a placebo. Participants will be given a 1-day run-in diet prior to each study day to support energy balance. On each study day visit, participants will undergo a resting metabolic rate test (indirect calorimetry) followed by a fasting appetite rating and blood sample collection. Participants will then be provided with a standard breakfast meal (one with the ketone supplement and one with placebo). Appetite ratings and blood sample collection will be repeated 60, 120, and 180 minutes after the meal. Indirect calorimetry will be completed after the 30, 90, and 150 minute assessments. After the 180-minute timepoint, participants will be provided with a buffet-like lunch meal with instructions to eat as much or as little as they would like to determine ad libitum dietary intake at a single meal. To assess free-living ad libitum dietary intake, participants will receive 1.5 days of food boxes tailored to their preferences, with uneaten food returned at the end of the 1.5-day period. This study will be the first to assess the impact of exogenous ketones on appetite in obesity and would help inform future weight loss intervention trials. Read Less

Gender:

ALL

Ages:

Between 19 years and 45 years

Trial Updated:

05/06/2024

Locations: University of British Columbia - Okanagan, Kelowna, British Columbia

Conditions: Appetite, Obesity, Ketones, Appetitive Behavior

Register for Updates

Learn More ›

Obesity Clinical Trials in Canada

Match to Clinical Trials